Metronidazole Baxter

Metronidazole, the active ingredient in Metronidazole Baxter, is a nitroimidazole antibiotic presented as an injection for intravenous use. It treats anaerobic bacterial infections and certain protozoal infections in adult patients. It is indicated for infections caused by susceptible anaerobic bacteria and selected protozoa, and is commonly used in hospital settings.

GNH USA supplies Metronidazole Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union quality standards and is distributed under strict Good Distribution Practice to ensure product integrity throughout the supply chain.

Metronidazole is a nitroimidazole antibiotic that targets anaerobic bacteria and certain protozoa.

- Anaerobic bacterial infections: effective against mixed anaerobic flora, reducing infection severity. - Intra‑abdominal infections: helps control polymicrobial infections within the abdominal cavity. - Pelvic inflammatory disease: eradicates causative anaerobes, improving pelvic health. - Bacterial vaginosis: restores normal vaginal flora by eliminating overgrowth of anaerobes. - Trichomoniasis: eliminates the protozoan parasite, relieving symptoms and preventing transmission.

Metronidazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient upset stomach often reported. - Metallic taste: distinctive taste sensation during therapy. - Headache: mild to moderate headache episodes. - Diarrhea: loose stools occurring during treatment.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate attention. - Peripheral neuropathy: tingling or numbness in extremities. - Stevens‑Johnson syndrome: severe skin reactions with blistering. - Severe allergic reactions: anaphylaxis, rash, or angioedema.

Before using Metronidazole, clinicians should consider several safety measures.

- Renal function assessment: evaluate kidney function prior to initiation. - Hepatic function monitoring: check liver enzymes during prolonged therapy. - Pregnancy timing: avoid use in the first trimester unless benefits outweigh risks. - Alcohol consumption: counsel patients to abstain to prevent disulfiram‑like reactions. - Dose adjustment in hepatic impairment: reduce dosage as recommended for liver dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazole can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: can reduce metronidazole plasma concentrations. - Cimetidine: may increase metronidazole levels, requiring monitoring.